Valeritas (OTCMKTS:VLRXQ) & Sight Sciences (NASDAQ:SGHT) Critical Contrast

Sight Sciences (NASDAQ:SGHT – Get Free Report) and Valeritas (OTCMKTS:VLRXQ – Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.

Institutional & Insider Ownership

55.5% of Sight Sciences shares are owned by institutional investors. 28.9% of Sight Sciences shares are owned by company insiders. Comparatively, 1.0% of Valeritas shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Sight Sciences and Valeritas, as provided by MarketBeat.com.

Sight Sciences presently has a consensus target price of $7.25, suggesting a potential upside of 39.16%. Given Sight Sciences’ higher probable upside, equities analysts clearly believe Sight Sciences is more favorable than Valeritas.

Profitability

This table compares Sight Sciences and Valeritas’ net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Sight Sciences and Valeritas”s gross revenue, earnings per share (EPS) and valuation.

Valeritas has lower revenue, but higher earnings than Sight Sciences.

Summary

Sight Sciences beats Valeritas on 5 of the 8 factors compared between the two stocks.

About Sight Sciences

(Get Free Report)

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.

About Valeritas

(Get Free Report)

Valeritas Holdings, Inc., a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey.